However, the application of CHK1 inhibitors is limited by tumor heterogeneity in breast cancer, in response to this problem, some studies have pointed out that the therapeutic effects of CHK1 inhibition are related to p53-deficiency 5. Here, CHEK1 is linked to hyperinsulinemic hypoglycemia, familial, 4.